Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS

Abstract

Get full access to this article

View all access options for this article.

References

Fox

. Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS – NO. Mult Scler 2016; 23: 506–508.

Chataway

. Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS – YES. Mult Scler 2016; 23: 505–506.

Lublin

Miller

Freedman

. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387: 1075–1084.

Novartis

. Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS | Novartis, https://www.novartis.com/news/media-releases/novartis-announces-positive-phase-iii-results-showing-efficacy-baf312-patients (2016, accessed 9 December 2016).

Hawker

O’Connor

Freedman

. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460–471.

Montalban

Hemmer

Rammohan

. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis: Results of the phase III double-blind, placebo-controlled ORATORIO study (S49.001). Neurology 2016; 86(16): Supplement S49.001.

Sormani

Bonzano

Roccatagliata

. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach. Ann Neurol 2009; 65: 268–275.

Raftopoulos

Hickman

Toosy

. Phenytoin for neuroprotection in patients with acute optic neuritis: A randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15: 259–269.

Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS – Commentary

Abstract

Get full access to this article

References